First-in-Human Study of ZE94-0605 for Advanced Solid Tumor Cancers
Tests ZE94-0605, a pill, in adults with advanced solid tumors.
Key facts
- Who runs it
- Eilean Therapeutics
- Where
- Tashkent, UzbekistanSee the siteAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 60 people, planned
- Started
- 25 Jun 2026
- Expected to end
- May 2028
- Type of study
- Interventional, 8 groups
- Treatments tested
- ZE94-0605
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an advanced solid tumor that has spread or cannot be removed by surgery, and that no longer responds to available treatments.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced, unresectable or metastatic solid tumor confirmed by tissue testing, with measurable disease. The tumor must be refractory to, or the person intolerant of, available therapies known to help.
- Earlier treatment
- The tumor must have stopped responding to, or the person could not tolerate, available therapies known to help. In the expansion part, people who declined such therapy can also join. No other investigational drug within 14 days or five half-lives, whichever is longer.
- Biomarker or test result
- In the expansion part (Phase 1b), CCNE1 amplification is required. The dose-escalation part (Phase 1a) does not require it.
Main reasons for not taking part
- Another cancer in the past, with a few listed exceptions
- Known active hepatitis C, hepatitis B, or HIV infection
- Pregnancy or breastfeeding
- Cannot take oral medication, for example due to bowel disease or stomach or small bowel resection
- Heart problems such as heart failure, unstable angina, serious rhythm problems, or QTcF 470 ms or more (unless a pacemaker is in place)
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Phase 1a Dose-Escalation Cohorts:
- Age ≥18 years, with a pathologically confirmed, advanced, unresectable or metastatic solid tumor refractory to, or intolerant of, available therapies known to provide clinical benefit for the participant's condition, if available, and with measurable disease; Phase 1b Dose-Expansion Cohorts:
- Age ≥18 years, with a pathologically confirmed, advanced, unresectable or metastatic solid tumor refractory to, or intolerant of, available therapies known to provide clinical benefit for the participant's condition, if available, or who has declined such therapy, with CCNE1 amplification and measurable disease; Common Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate end-organ function: creatinine clearance >60 mL/min; AST and ALT <3 × upper limit of normal (ULN); and total bilirubin <1.5 × ULN, except for participants with Gilbert's disease
- Absolute neutrophil count ≥1.5 × 10\^9/L and platelets ≥100 × 10\^9/L
- Female participants of childbearing potential must be willing to abstain from heterosexual intercourse or use a protocol-recommended contraceptive method from signing informed consent through treatment and for 90 days after the last study-drug dose
- Male participants of childbearing potential having intercourse with females of childbearing potential must be willing to abstain from heterosexual intercourse or use a protocol-recommended contraceptive method from signing informed consent through treatment and for 90 days after the last study-drug dose. Male participants must refrain from sperm donation for the same period
- Willingness to comply with scheduled visits, drug administration, imaging, laboratory tests, other study procedures, and restrictions
Who cannot take part
- Concurrent participation in an investigational-drug trial with therapeutic intent or receipt of an investigational agent within 14 days or five half-lives (whichever is longer) before the first study dose; if half-life is unknown, a minimum 14-day washout is required. An investigational agent is one without an approved indication from the U.S. FDA
- Current use of or anticipated need for a medication or therapy prohibited under protocol Section 7.6.2 during the applicable prohibited period, including proton pump inhibitors, prohibited strong CYP3A4 inducers, and prohibited concomitant anticancer treatments; relevant use of strong CYP3A4 inhibitors requires protocol-directed review
- Known active hepatitis C, hepatitis B, or HIV infection
- Inability to tolerate oral medication, including symptomatic gastrointestinal disease significantly affecting gastrointestinal function, such as inflammatory bowel disease or resection of the stomach or small bowel
- Uncontrolled intercurrent illness, including symptomatic congestive heart failure, unstable angina, serious cardiac arrhythmia, New York Heart Association Class III/IV heart failure, severe uncontrolled ventricular arrhythmia, or ECG evidence of acute ischemia or active conduction-system abnormality; or comorbidities that preclude safety evaluation of ZE94-0605
- Psychological, familial, social, or geographic factors, another significant medical condition, or laboratory abnormalities that preclude informed consent or adherence, hamper compliance with treatment/follow-up, or confound interpretation
- QT interval corrected by Fridericia (QTcF) ≥470 ms unless the participant has a pacemaker. Participants with incomplete or complete bundle branch block may participate following cardiology clearance. A pacemaker does not automatically exclude participation, but device and lead compatibility and institutional MRI safety clearance are required when MRI is necessary. If required MRI cannot be safely performed, the participant is ineligible unless the Sponsor Medical Monitor approves an alternative imaging method acceptable for central response assessment; Note: This text is faithfully condensed for a public registry; original criterion numbering differs. The protocol places the newly prohibited medication reconciliation instruction at the end of exclusion criterion 9; keep this in investigator instructions rather than individual eligibility criteria, unless preferred by sponsor; Note: Especially material changes: contraceptive window for women 90 days (older entry used 30 days); washout changed to longer of 14 days or 5 half-lives; PPI exclusion; newly explicit MRI/pacemaker safeguards
- History of another malignancy, except adequately treated localized basal-cell or squamous-cell skin cancer, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease, or another cancer in complete remission without treatment for ≥2 years, or one with an anticipated 24-month life expectancy that does not require treatment confounding study assessments. Such cases must be discussed with the Sponsor Medical Monitor before screening for enrollment
- Pregnancy or breastfeeding
Where in Uzbekistan
Also in 1 other country, 2 sites
- Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology UzbekistanTashkent, UzbekistanContact: Dilshod RafievTaking people
About the trial
What the trial wants to find out
ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors. Phase 1a will use sequential dose escalation to determine the maximally tolerated dose and biologically effective dose. Phase 1b will randomize participants with CCNE1 amplification between two dose levels to select the recommended Phase 2 dose.
The 8 groups in the trial
- Phase 1a Dose Level -1: ZE94-0605 50 mg QDTreatment being tested
Optional dose-reduction cohort. Participants will receive ZE94-0605 50 mg orally once daily in the fasted state in continuous 28-day cycles. This dose level will be evaluated only if Dose Level 1 is not tolerated.
Treatment: ZE94-0605
- Phase 1a Dose Level 1: ZE94-0605 100 mg QDTreatment being tested
Participants will receive ZE94-0605 100 mg orally once daily in the fasted state in continuous 28-day cycles.
Treatment: ZE94-0605
- Phase 1a Dose Level 2: ZE94-0605 200 mg QDTreatment being tested
Participants will receive ZE94-0605 200 mg orally once daily in the fasted state in continuous 28-day cycles.
Treatment: ZE94-0605
- Phase 1a Dose Level 3: ZE94-0605 350 mg QDTreatment being tested
Participants will receive ZE94-0605 350 mg orally once daily in the fasted state in continuous 28-day cycles.
Treatment: ZE94-0605
- Phase 1a Dose Level 4: ZE94-0605 500 mg QDTreatment being tested
Participants will receive ZE94-0605 500 mg orally once daily in the fasted state in continuous 28-day cycles.
Treatment: ZE94-0605
- Phase 1a Dose Level 5: ZE94-0605 650 mg QDTreatment being tested
Participants will receive ZE94-0605 650 mg orally once daily in the fasted state in continuous 28-day cycles. If the maximally tolerated dose or biologically effective dose has not been identified, subsequent dose levels may increase by approximately 33% following Safety Review Committee review.
Treatment: ZE94-0605
- Phase 1b Expansion Dose A: ZE94-0605 at the MTD or BEDTreatment being tested
Approximately 15 eligible participants with CCNE1 amplification are randomized to receive ZE94-0605 at the MTD or biologically effective dose selected from Phase 1a, orally once daily in the fasted state in continuous 28-day cycles.
Treatment: ZE94-0605
- Phase 1b Expansion Dose B: ZE94-0605 One Level Below MTD or BEDTreatment being tested
Approximately 15 eligible participants with CCNE1 amplification are randomized to receive ZE94-0605 at one dose level below the MTD or biologically effective dose selected from Phase 1a, orally once daily in the fasted state in continuous 28-day cycles.
Treatment: ZE94-0605
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1, First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
- Plain-language title
- First-in-Human Study of ZE94-0605 for Advanced Solid Tumor CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026